Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study

Addition of intravenous amikacin and clofazimine to recommended rifamycin-ethambutol-macrolide regimens yields favourable outcomes in severe M. avium complex pulmonary disease (MAC-PD). This five-drug regimen should be considered in select MAC-PD patients. https://bit.ly/30dxdRj

Detalles Bibliográficos
Autores principales: Zweijpfenning, Sanne M.H., Kops, Stephan E.P., Boeree, Martin J., Kuipers, Saskia, van Ingen, Jakko, Hoefsloot, Wouter, Magis-Escurra, Cecile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607114/
https://www.ncbi.nlm.nih.gov/pubmed/34820449
http://dx.doi.org/10.1183/23120541.00466-2021
_version_ 1784602490848673792
author Zweijpfenning, Sanne M.H.
Kops, Stephan E.P.
Boeree, Martin J.
Kuipers, Saskia
van Ingen, Jakko
Hoefsloot, Wouter
Magis-Escurra, Cecile
author_facet Zweijpfenning, Sanne M.H.
Kops, Stephan E.P.
Boeree, Martin J.
Kuipers, Saskia
van Ingen, Jakko
Hoefsloot, Wouter
Magis-Escurra, Cecile
author_sort Zweijpfenning, Sanne M.H.
collection PubMed
description Addition of intravenous amikacin and clofazimine to recommended rifamycin-ethambutol-macrolide regimens yields favourable outcomes in severe M. avium complex pulmonary disease (MAC-PD). This five-drug regimen should be considered in select MAC-PD patients. https://bit.ly/30dxdRj
format Online
Article
Text
id pubmed-8607114
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-86071142021-11-23 Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study Zweijpfenning, Sanne M.H. Kops, Stephan E.P. Boeree, Martin J. Kuipers, Saskia van Ingen, Jakko Hoefsloot, Wouter Magis-Escurra, Cecile ERJ Open Res Research Letters Addition of intravenous amikacin and clofazimine to recommended rifamycin-ethambutol-macrolide regimens yields favourable outcomes in severe M. avium complex pulmonary disease (MAC-PD). This five-drug regimen should be considered in select MAC-PD patients. https://bit.ly/30dxdRj European Respiratory Society 2021-11-22 /pmc/articles/PMC8607114/ /pubmed/34820449 http://dx.doi.org/10.1183/23120541.00466-2021 Text en Copyright ©The authors 2021 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Research Letters
Zweijpfenning, Sanne M.H.
Kops, Stephan E.P.
Boeree, Martin J.
Kuipers, Saskia
van Ingen, Jakko
Hoefsloot, Wouter
Magis-Escurra, Cecile
Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
title Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
title_full Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
title_fullStr Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
title_full_unstemmed Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
title_short Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
title_sort treatment of severe mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
topic Research Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607114/
https://www.ncbi.nlm.nih.gov/pubmed/34820449
http://dx.doi.org/10.1183/23120541.00466-2021
work_keys_str_mv AT zweijpfenningsannemh treatmentofseveremycobacteriumaviumcomplexpulmonarydiseasewithadjunctiveamikacinandclofazimineversusstandardregimenalonearetrospectivestudy
AT kopsstephanep treatmentofseveremycobacteriumaviumcomplexpulmonarydiseasewithadjunctiveamikacinandclofazimineversusstandardregimenalonearetrospectivestudy
AT boereemartinj treatmentofseveremycobacteriumaviumcomplexpulmonarydiseasewithadjunctiveamikacinandclofazimineversusstandardregimenalonearetrospectivestudy
AT kuiperssaskia treatmentofseveremycobacteriumaviumcomplexpulmonarydiseasewithadjunctiveamikacinandclofazimineversusstandardregimenalonearetrospectivestudy
AT vaningenjakko treatmentofseveremycobacteriumaviumcomplexpulmonarydiseasewithadjunctiveamikacinandclofazimineversusstandardregimenalonearetrospectivestudy
AT hoefslootwouter treatmentofseveremycobacteriumaviumcomplexpulmonarydiseasewithadjunctiveamikacinandclofazimineversusstandardregimenalonearetrospectivestudy
AT magisescurracecile treatmentofseveremycobacteriumaviumcomplexpulmonarydiseasewithadjunctiveamikacinandclofazimineversusstandardregimenalonearetrospectivestudy

Ejemplares similares